1[1]Brooks P, Emery P, Evans JF, et al. Interpreting the clinical significance of the differential inhibition of cyclooxygenaseiand cyclooxygenase-2. Rheumatology, 1999, 38(8) :779-788.
2[2]Langenbach R, Loftin C, Lee C, et al. Cyclooxygenase knockout mice models for elucidating isoform-specific functions. Biochem Pharmacol,1999, 58(8): 1237-1246.
3[3]Freston JW. Rationalizing Cyclooxygenase(COX) inhibition for maximal efficacy and minimal adverse events. Am J Med, 1999, 107(6A):78s-89s.
4[4]Van Ryn J, Pairet M. Clinical experience with cyclooxygenase-2 inhibitors. Inflamm Res, 1999, 48(5): 247-254.
5[5]Bjorkman DJ. Current status of non-steroidal anti-inflammatory drug (NSAID) use in the united states: risk factors and frequency of complications. Am J Med, 1999, 107(6A) :3s-10s.
6[6]Furst DE. Pharmacology and efficacy of cyclooxygenase (COX) inhibitors. Am J Med, 1999, 107(6A): 18s-22s.
7[7]Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med, 1999, 5(12):1418-1823.
8[8]Gabriel SE, Jaalkkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of non-steroidal anti-inflammatory drugs. A mets-analysis Ann Intern Med, 1991,115(10) :787-796.
9[9]Maricic N, Ehrlich K, Gretzer B, et al. Selective cydo-oxygenase-2inhibitors aggravate ischaemia-reperfusion injury in the rat stomach. Br J Pharmacol 1999, 128(8): 1659-66.
10[10]Reuben SS, Steinberg R. Gastric perforation associated with the use of celecoxib. Anesthesiology, 1999, 91(5): 1548-1549.
